4-(1H-1,2,4-triazol-1-yl)-3-(trifluoromethyl)aniline | 351325-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1H-1,2,4-triazol-1-yl)-3-(trifluoromethyl)aniline
• 英文别名: 4-[1,2,4]triazol-1-yl-3-trifluoromethyl-phenylamine；4-(1,2,4-triazol-1-yl)-3-(trifluoromethyl)aniline
• CAS: 351325-27-4
• 化学式: C₉H₇F₃N₄
• mdl: MFCD12768357
• 分子量: 228.177
• InChiKey: JZVZWJBLEPZALK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(1H-1,2,4-triazol-1-yl)-3-(trifluoromethyl)aniline 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 1-(4-(1H-1,2,4-triazol-1-yl)-3-(trifluoromethyl)phenyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)urea
  参考文献：
  名称：

  Synthesis and SAR studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives as potent inhibitors of Bloom helicase

  摘要：

  Human cells utilize a variety of complex DNA repair mechanisms in order to combat constant mutagenic and cytotoxic threats from both exogenous and endogenous sources. The RecQ family of DNA helicases, which includes Bloom helicase (BLM), plays an important function in DNA repair by unwinding complementary strands of duplex DNA as well as atypical DNA structures such as Holliday junctions. Mutations of the BLM gene can result in Bloom syndrome, an autosomal recessive disorder associated with cancer predisposition. BLM-deficient cells exhibit increased sensitivity to DNA damaging agents indicating that a selective BLM inhibitor could be useful in potentiating the anticancer activity of these agents. In this work, we describe the medicinal chemistry optimization of the hit molecule following a quantitative high-throughput screen of >355,000 compounds. These efforts lead to the identification of ML216 and related analogs, which possess potent BLM inhibition and exhibit selectivity over related helicases. Moreover, these compounds demonstrated cellular activity by inducing sister chromatid exchanges, a hallmark of Bloom syndrome. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.08.025
• 作为产物：
  描述：

  2-氟-5-硝基三氟甲苯 、 1H-1,2,4-三唑 生成 4-(1H-1,2,4-triazol-1-yl)-3-(trifluoromethyl)aniline
  参考文献：
  名称：

  1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

  摘要：

  该发明涉及公式（I）的新有机化合物，其制备方法，其在人或动物体内治疗过程中的应用，其单独或与一种或多种其他药物活性化合物结合使用，用于治疗炎症或阻塞性呼吸道疾病，例如哮喘，与移植有关的常见疾病或增殖性疾病，例如肿瘤疾病。

  公开号：

  US07667039B2

文献信息

• [EN] N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES<br/>[FR] DÉRIVÉS DE N-(4-(OXAZOL-5-YL) PHÉNYL)CHROMANE-3-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QUE STIMULATEURS DE LA PRODUCTION DE CELLULES PRÉCURSEURS RÉTINIENNES POUR LE TRAITEMENT DE MALADIES NEURORÉTINIENNES
  申请人：ENDOGENA THERAPEUTICS INC

  公开号：WO2020140050A1

  公开（公告）日：2020-07-02

  New compounds and to a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, comprising administering compound of the formula (I) or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is a is selected from the group consisting of a 5-oxazolyl, a pyridine-4-yl, a triazolyl, a oxadiazolyl, a imidazolyl and a 2-methyloxazol-5-yl residue, R1, and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX) wherein, II*II denotes the point of attachment to the remainder of the molecule, and R2, R3, R4, R5, R2 I, R3 I, R4 I, R5 I, R2 II, R3 II R4 II, R5 II, R2 III, R3 III, R4 III, R5 III, R2 IV, R3 IV, R4 IV, R5 IV, R2 V, R3 V, R4 V, R5 V , R2 VI, R3 VI, R4 VI, R5 VI,R2 VII, R3 VII, R4 VII, R5 VII, are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, 2,2,2-trifluoromethyl and difluoromethoxy.

  新化合物及治疗导致光感受器丧失或外视网膜退化的视网膜疾病的方法，包括给予式(I)的化合物或其药学上可接受的盐、消旋混合物、相应对映体或如适用的话，相应的二对映体，其中：A选自由5-噁唑基、吡啶-4-基、三唑基、噁二唑基、咪唑基和2-甲氧基噁唑-5-基残基的群组，R1和R12独立选自氢、氟、氯、甲氧基、三氟甲基、甲基和二氟甲氧基的群组，B选自式(II)、(III)、(IV)、(V)、(VI)、(VII)、(VIII)和(IX)的残基的群组，其中，II*II表示与分子其余部分的连接点，R2、R3、R4、R5、R2 I、R3 I、R4 I、R5 I、R2 II、R3 II、R4 II、R5 II、R2 III、R3 III、R4 III、R5 III、R2 IV、R3 IV、R4 IV、R5 IV、R2 V、R3 V、R4 V、R5 V、R2 VI、R3 VI、R4 VI、R5 VI、R2 VII、R3 VII、R4 VII、R5 VII独立选自氢、具有1至3个碳原子的直链或支链烷基、氟、氯、溴、甲氧基、乙氧基、丙氧基、2,2,2-三氟甲基和二氟甲氧基的群组。
• 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors
  申请人：Garcia-Echeverria Carlos

  公开号：US20080194579A1

  公开（公告）日：2008-08-14

  The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

  本发明涉及公式（I）的新有机化合物，其制备方法，其在治疗人体或动物的过程中的应用，其单独或与一种或多种其他药物活性化合物结合使用，用于治疗炎症或阻塞性呼吸道疾病，如哮喘，与移植相关的常见疾病或增生性疾病，如肿瘤疾病。
• 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS
  申请人：Garcia-Echeverria Carlos

  公开号：US20100056558A1

  公开（公告）日：2010-03-04

  The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

  本发明涉及公式（I）的新有机化合物，其制备方法，其在处理人或动物体的过程中的应用，其单独使用或与一个或多个其他药物活性化合物结合使用，用于治疗炎症或阻塞性呼吸道疾病，如哮喘，与移植有关的常见疾病或增生性疾病，如肿瘤疾病。
• 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors
  申请人：Novartis AG

  公开号：US07994170B2

  公开（公告）日：2011-08-09

  The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

  本发明涉及式(I)的新型有机化合物，其制备方法，应用于人或动物体内处理过程，使用该化合物-单独或与一种或多种其他药物活性化合物结合-用于治疗炎症或阻塞性呼吸道疾病，如哮喘，常见于移植相关疾病或增生性疾病，如肿瘤疾病。
• Imidazoquinolines as lipid kinase inhibitors
  申请人：Garcia-Echeverria Carlos

  公开号：US20120207751A1

  公开（公告）日：2012-08-16

  The invention relates to a combination comprising compounds of formula (I) and one or more other antiproliferative compounds, hormones or radiation, pharmaceutical preparations comprising the combination thereof, and the application thereof in a process for the treatment of tumors.

  本发明涉及一种组合物，包括式(I)的化合物和一种或多种其他抗增殖化合物、激素或辐射，以及包含该组合物的药物制剂，以及其在肿瘤治疗过程中的应用。